JP2021525266A5 - - Google Patents

Info

Publication number
JP2021525266A5
JP2021525266A5 JP2020565864A JP2020565864A JP2021525266A5 JP 2021525266 A5 JP2021525266 A5 JP 2021525266A5 JP 2020565864 A JP2020565864 A JP 2020565864A JP 2020565864 A JP2020565864 A JP 2020565864A JP 2021525266 A5 JP2021525266 A5 JP 2021525266A5
Authority
JP
Japan
Application number
JP2020565864A
Other languages
Japanese (ja)
Other versions
JPWO2019224779A5 (https=
JP7344911B2 (ja
JP2021525266A (ja
Filing date
Publication date
Priority claimed from GBGB1808564.7A external-priority patent/GB201808564D0/en
Application filed filed Critical
Publication of JP2021525266A publication Critical patent/JP2021525266A/ja
Publication of JPWO2019224779A5 publication Critical patent/JPWO2019224779A5/ja
Publication of JP2021525266A5 publication Critical patent/JP2021525266A5/ja
Application granted granted Critical
Publication of JP7344911B2 publication Critical patent/JP7344911B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565864A 2018-05-24 2019-05-23 頸部障害の処置のためのロピナビルおよびリトナビル Active JP7344911B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1808564.7A GB201808564D0 (en) 2018-05-24 2018-05-24 Treatments
GB1808564.7 2018-05-24
PCT/IB2019/054292 WO2019224779A1 (en) 2018-05-24 2019-05-23 Lopinavir and ritonavir for the treatment of cervix disorders

Publications (4)

Publication Number Publication Date
JP2021525266A JP2021525266A (ja) 2021-09-24
JPWO2019224779A5 JPWO2019224779A5 (https=) 2023-07-19
JP2021525266A5 true JP2021525266A5 (https=) 2023-07-19
JP7344911B2 JP7344911B2 (ja) 2023-09-14

Family

ID=62812406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565864A Active JP7344911B2 (ja) 2018-05-24 2019-05-23 頸部障害の処置のためのロピナビルおよびリトナビル

Country Status (12)

Country Link
US (2) US11738024B2 (https=)
EP (1) EP3801509A1 (https=)
JP (1) JP7344911B2 (https=)
CN (1) CN112203656B (https=)
AU (1) AU2019274812B2 (https=)
BR (1) BR112020023964A2 (https=)
CA (1) CA3100425A1 (https=)
GB (1) GB201808564D0 (https=)
MX (1) MX2020012656A (https=)
SG (1) SG11202010138WA (https=)
WO (1) WO2019224779A1 (https=)
ZA (1) ZA202006324B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201907305D0 (en) 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
GB201917252D0 (en) * 2019-11-27 2020-01-08 Pharmaceutic compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
DK2269591T3 (en) * 2000-01-19 2018-07-16 Abbvie Inc IMPROVED PHARMACEUTICAL FORMULATIONS
CA2445967A1 (en) 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
US20030129208A1 (en) 2002-01-07 2003-07-10 Alberts David S. Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses
WO2004010937A2 (en) 2002-07-26 2004-02-05 Advanced Research & Technology Institute At Indiana University Method of treating cancer
BR0302523A (pt) 2003-07-23 2005-04-05 Cristalia Prod Quimicos Farm Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2582559A1 (en) 2003-11-28 2005-06-16 The University Of Manchester Treatment of hpv infections and cancer
WO2008088806A1 (en) 2007-01-16 2008-07-24 Johns Hopkins University Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants
EP2280690A2 (en) 2008-04-18 2011-02-09 Nanobio Corporation Methods for treating herpes virus infections
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
KR20130139896A (ko) 2010-09-08 2013-12-23 프로노바 바이오파마 너지 에이에스 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물
GB201115635D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
PL3060211T3 (pl) 2013-10-23 2020-07-27 The University Of Manchester Leczenie nowotworu i łagodnych chorób proliferacyjnych
WO2016123541A2 (en) 2015-01-30 2016-08-04 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of encephalitis infection
WO2019130341A1 (en) 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201808567D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201808571D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201907305D0 (en) 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
GB201917252D0 (en) 2019-11-27 2020-01-08 Pharmaceutic compositions

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021018450A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016138A2 (https=)
BR112019016142A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
JP2021525266A5 (https=)
BR112021015080A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)
BR112021013128A2 (https=)
BR112021018484A2 (https=)